Rising Demand For Cell & Gene Therapy Manufacturing Services Market


Posted June 20, 2022 by NeilR112

The large share of the North American market is attributed to the rising government funding for R&D into personalized & efficient therapeutics.
 
[299 Pages Report] The global cell and gene therapy manufacturing services size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. The market is primarily driven by the prevalence of cancer and other target diseases. The development of therapies for key diseases, such as cancer, has attracted significant attention. Furthermore, increasing investments of pharmaceutical companies in the development of novel drugs is also fueling the market growth.



The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.



According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development.



Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441



In addition to this, according to data released by CGT Catapult, there were 154 ATMP clinical trials ongoing in the UK in 2020 compared to the 127 trials reported in 2019, indicating an increase of more than 20%. This significant growth in the number of cell & gene therapy clinical trials is expected to drive the demand for manufacturing services and, in turn, propel growth in the cell & gene therapy manufacturing services market.



5dc11a20678b95ed4e210d0186696672.jpg

In 2020, cell therapy segment dominated the cell & gene therapy manufacturing services. This can be attributed to the advent of new technologies and innovative products that have enabled several variety of cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, natural killer cells, dendritic cells, and T-cells to treat diseases and conditions.



In 2020, the academic and research institutes segment accounted for the second largest share of the market by end users. Increase in life sciences R&D expenditure coupled with growing government support for research is driving the market growth for this segment.



Key players in the cell and gene therapy manufacturing services market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Charles River Laboratories (US), Lonza (Switzerland), Catalent (US), WuXi AppTec (China), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MnM
Country United Kingdom
Categories Health , Medical , News
Tags cell , gene
Last Updated June 20, 2022